Bladder Wall Thickness in Symptomatic Urinary Stress Incontinence and Its Correlation with Urodynamics Results

Launched by IRCCS SAN RAFFAELE · Dec 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to evaluate women who experience stress urinary incontinence (SUI), a condition where urine leaks during activities like coughing or exercising. The study aims to see if measuring the thickness of the bladder wall using ultrasound can help determine if there are any issues with bladder function, particularly focusing on a condition called detrusor overactivity, which can cause urgency or leakage. By comparing these ultrasound measurements with results from a standard bladder test (called urodynamics), researchers hope to find a non-invasive method to better diagnose SUI and potentially improve treatment options.

To participate, women over 18 who have symptoms of SUI and are seeking evaluation at a urogynecology clinic may be eligible. Participants will undergo an ultrasound to measure bladder wall thickness and also have a urodynamic examination to assess their bladder function. It’s important to note that certain individuals, such as those with specific bladder issues or previous surgeries, may not qualify for the study. This research could lead to better diagnosis and treatment strategies for women suffering from urinary incontinence, helping to enhance their quality of life.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Participant is willing and able to give informed consent for participation in the study.
• • 2. Women aged \> 18 y.o.
• • 3. Women symptomatic for pure or predominant stress incontinence attending the urogynecology outpatient clinic at our institution.
• • 4. Patients undergoing urogynecological standard evaluation for their symptoms, including outpatient gynecological visit and a transvaginal ultrasound.
• • 5. Patients undergoing invasive urodynamic examination for objective assessment of their symptoms or in preparation for possible anti-incontinence surgery.
• Exclusion Criteria:
• • 1. Patients with pure or predominant OAB symptomatology
• • 2. Current use of antimuscarinic agents or beta3-agonists (for example Mirabegron)
• • 3. Presence of urological or gynecological cancer.
• • 4. Patients with previous anti-incontinence surgery.
• • 5. Patients with pelvic organ prolapse \> II stage.
• • 6. Patients with chronic bladder retention.
• • 7. Patients with neurological diseases that may affect bladder function and urodynamic results.
• • 8. Participants unwilling or unable to give informed consent for participation in the study.